Affordable Access

Access to the full text

Changing the tone of clinical study design in the cannabis industry

Authors
  • Antony, Joseph M1
  • McDonald, Alison C.1
  • Noorbakhsh, Farshid2
  • Guthrie, Najla1
  • Evans, Mal1
  • 1 KGK Science London, Canada , (Canada)
  • 2 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Iran , (Iran)
Type
Published Article
Journal
Translational Neuroscience
Publisher
De Gruyter
Publication Date
Feb 13, 2020
Volume
11
Issue
1
Pages
4–9
Identifiers
DOI: 10.1515/tnsci-2020-0002
Source
De Gruyter
Keywords
License
Green

Abstract

Cannabis (also known as marijuana) is the most frequently used psychoactive substance globally. Cannabis exerts therapeutic functions for many indications and has vast potential as a health and wellness product. Advances in our understanding of the composition and pharmacological properties of cannabis have revealed interactions between cannabis, an individuals’ circadian rhythms and their endocannabinoid signaling. Exogenously administered cannabinoids can bidirectionally entrain central and peripheral clocks that comprise circadian rhythms, and malfunctions in the endocannabinoid system are reported to impact neurological processes. Therefore, it is necessary to account for the circadian rhythm when designing clinical trials examining the pharmacological properties of cannabis-based products for health and wellness to limit its potential confounding impact on results. Consideration of the entrainment capabilities of the endocannabinoid system is warranted when designing clinical trials.

Report this publication

Statistics

Seen <100 times